Feeds:
Posts
Comments

Posts Tagged ‘abiraterone acetate’

BLOOMBERG BUSINESSWEEK: A US company will next month report the results of its study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer, also called castration-resistant prostate cancer. READ MORE>

Read Full Post »

URO TODAY:  Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have  not had chemotherapy.

A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>

Read Full Post »

URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen. READ MORE>

Notably, promising activity has been shown in early phase trials by MDV3100, a new anti-androgen designed for activity in prostate cancer model systems with over-expressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumour. Both agents are undergoing phase three testing.

Read Full Post »

JULY 12: ASSOCIATED PRESS: Johnson & Johnson says it has completed its $US893.7 million acquisition of Cougar Biotechnology Inc, a development stage company that is testing a potential vaccine for prostate cancer. Los Angeles-based Cougar is conducting two late stage clinical trials of abiraterone acetate as a treatment for prostate cancer. READ MORE>

Read Full Post »

JUNE 19: REUTERS HEALTH: Abiraterone acetate leads to significant declines in prostate-specific antigen (PSA) in men with castration-resistant prostate cancer, an aggressive form of the disease. READ MORE>

Read Full Post »

JUNE 1: NEW PROSTATE CANCER INFO-LINK: Abiraterone acetate does in fact work in patients who have been previously treated with ketoconazole — but it definitely doesn’t seem to work as well in these patients as it does in the ketoconazole-naive patients, writes Mike Scott from the US oncologists conference. READ MORE> on this and other papers.

Read Full Post »

MAY 28: NEW JERSEY BUSINESS NEWS: Cougar Biotechnology, the developer of cancer medicines that Johnson & Johnson agreed to buy last week, said its lead experimental drug worked against prostate tumours in a company-sponsored study. READ MORE>

Read Full Post »